# William D. Tap

Source: https://onco.cc/people/william-tap/  
OnCo record `william-tap` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Sarcoma oncologist who led ANNOUNCE and the pexidartinib trial that produced the first drug for tenosynovial giant cell tumour.

## Summary

William Tap led ANNOUNCE, the phase 3 trial that found olaratumab did not improve survival in soft-tissue sarcoma despite a striking phase 2 result, a widely cited cautionary tale for accelerated approval, and ENLIVEN, which won pexidartinib approval for tenosynovial giant cell tumour. He chairs the Alliance sarcoma committee and leads sarcoma medical oncology at MSKCC.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: sarcoma; trialist
- Role: Chief, Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center
- Specialisms: Soft-tissue sarcoma; Tenosynovial giant cell tumour; Kinase inhibitors; Trial design

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Tap%20WD%5BAuthor%5D%20sarcoma

## Connected records

- cancers: [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- institutions: [Memorial Sloan Kettering Cancer Center](https://onco.cc/institutions/mskcc/)
- trials: [ANNOUNCE](https://onco.cc/trials/announce/)

---
JSON: https://onco.cc/api/v1/entities/william-tap.json